Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ajcp/aqaf128 http://scihub22266oqcxt.onion/10.1093/ajcp/aqaf128 41370001!?!41370001 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41370001&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Am+J+Clin+Pathol 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41370001|t=2025. Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience |pdf=|usr=}}{{41370001}} gab.com Text Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience JO: Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=41370001 #FOAvip OBJECTIVE: ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis. METHODS: We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered. RESULTS: ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease. CONCLUSIONS: Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients. Twit Text FOAVip Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience ????Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=41370001 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41370001 #FOAvip English Wikipedia <ref>{{Cite pmid|41370001}}</ref> Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience #MMPMID41370001 Humble RM; Paturu R; Xiao H; Yang C; Iwata-Otsubo A; Dhanasekaran SM; Brown NA; Betz BL; Kim AS; Myers JL; Chinnaiyan AM; Shao L; Mehra R Am J Clin Pathol 2025[Dec]; ? (?): ? PMID41370001show ga OBJECTIVE: ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis. METHODS: We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered. RESULTS: ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease. CONCLUSIONS: Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients. ?Clinical ERG break-apart fluorescence in situ hybridization assay: pra(epmc).pdf DeepDyve Pubget Overpricing